Atorvastatin for heart protection during AML/NHL chemo
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This trial tests if the medicine atorvastatin can protect the heart during chemotherapy for acute myeloid leukemia or non-Hodgkin lymphoma. It may help prevent heart damage from cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either acute myeloid leukemia (treated with 3+7 chemo) or non-Hodgkin lymphoma (treated with CHOP chemo).
- Your heart function (ejection fraction) is 60% or higher.
- You do not have other blood cancers.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether a blood-pressure medicine plan (a beta blocker plus lisinopril) can protect the heart in people newly diagnosed with acute myeloid leukemia (AML) who are starting anthracycline chemotherapy. It looks at heart safety by requiring a good heart scan before treatment and careful medication eligibility.
This trial tests whether common heart medicines (statins or ACE-inhibitors) can protect the heart during cancer radiation therapy. It is for adults who are about to start chest radiation and have not taken these drugs before.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.